

# The Lack of Antitumor Effects of o,p'DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment.

Sécolène Hescot, Angelo Paci, Atmane Seck, Abdelhamid Slama, Say Viengchareun, Séverine Trabado, Sylvie Brailly-Tabard, Abir Al Ghuzlan, Jacques Young, Eric Baudin, et al.

► **To cite this version:**

Sécolène Hescot, Angelo Paci, Atmane Seck, Abdelhamid Slama, Say Viengchareun, et al.. The Lack of Antitumor Effects of o,p'DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment.: o,p'DDA is not an active metabolite of mitotane. *Hormones & cancer*, New York, NY : Springer Science + Business Media, 2014, epub ahead of print. <10.1007/s12672-014-0189-7>. <inserm-01026154>

**HAL Id: inserm-01026154**

**<http://www.hal.inserm.fr/inserm-01026154>**

Submitted on 20 Jul 2014

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **The lack of antitumor effects of o,p’DDA excludes its role as an active**  
2 **metabolite of mitotane for adrenocortical carcinoma treatment**

3  
4 *Sékolène Hescot<sup>1,2,3</sup>, Angelo Paci<sup>4</sup>, Atmane Seck<sup>4</sup>, Abdelhamid Slama<sup>5</sup>, Say Viengchareun<sup>1,2</sup>,*  
5 *Séverine Trabado<sup>1,2,6</sup>, Sylvie Brailly-Tabard,<sup>1,2,6</sup>Abir Al Ghuzlan<sup>7</sup> , Jacques Young<sup>1,2,8</sup>, Eric*  
6 *Baudin<sup>1,2,3</sup>, Marc Lombès<sup>1,2,8</sup>.*

7 <sup>1</sup> Inserm U693, Le Kremlin Bicêtre, France;

8 <sup>2</sup> Univ Paris-Sud, Faculté de Médecine Paris-Sud, UMR-S693, Le Kremlin-Bicêtre, France;

9 <sup>3</sup> Department of Nuclear Medicine and Endocrine Tumors, GustaveRoussy Cancer Campus Grand Paris, Villejuif,  
10 France;

11 <sup>4</sup> Pharmacology and Drug Analysis Department, GustaveRoussy Cancer Campus Grand Paris, Villejuif, France;

12 <sup>5</sup> Assistance Publique, Hôpitaux de Paris, Service de Biochimie, CHU Bicêtre, Le Kremlin Bicêtre, France;

13 <sup>6</sup> Assistance Publique, Hôpitaux de Paris, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie,  
14 CHU Bicêtre, Le Kremlin Bicêtre, France;

15 <sup>7</sup> Department Medical Biology and Pathology, GustaveRoussy Cancer Campus Grand Paris, Villejuif, France;

16 <sup>8</sup> Assistance Publique, Hôpitaux de Paris, Service d’Endocrinologie et des Maladies de la Reproduction, CHU  
17 Bicêtre, Le Kremlin Bicêtre, France.

18

19 **Short title:** o,p’DDA is not an active metabolite of mitotane

20 Correspondence should be addressed to:

21 Marc Lombès, Inserm U693, Fac Med Paris Sud, 63 rue Gabriel Péri, 94276 Le Kremlin-Bicêtre

22 Cedex, France

23 Email : [marc.lombes@u-psud.fr](mailto:marc.lombes@u-psud.fr); phone: +33149596702; fax: +33149596732

24 **Keywords:** Adrenocortical carcinoma, mitotane, o,p’-DDD, o,p’-DDA

25

26 Word count: 4052

## 27 **Abstract**

28 Mitotane (o,p'DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but  
29 its mechanism of action remains unknown. Previous studies suggested that o,p'DDA may represent  
30 the active metabolite of mitotane. We aimed at re-evaluating the potential role and pharmacological  
31 effects of o,p'DDA. Functional consequences of o,p'DDA exposure were studied on proliferation,  
32 steroidogenesis and mitochondrial respiratory chain in human H295R and SW13 adrenocortical cells.  
33 Mitotane and its metabolites were quantified using HPLC-UV in these cells treated with o,p'DDD or  
34 o,p'DDA and in human adrenal tissues. Dose-response curves up to 300  $\mu$ M showed that, as opposed  
35 to o,p'DDD, o,p'DDA did not inhibit cell proliferation, nor alter respiratory chain complex IV activity,  
36 gene expression nor induce mitochondrial biogenesis, oxidative stress or apoptosis. However, whereas  
37 mitotane drastically decreased expression of genes involved in steroidogenesis, o,p'DDA slightly  
38 reduced expression of some steroidogenic enzymes yet exerts weak anti-secretory effects only at high  
39 doses. While o,p'DDD concentration was significantly reduced by 40% in H295R cell supernatants  
40 after 48 h incubation, o,p'DDA levels remained unchanged suggesting that o,p'DDA was not  
41 efficiently transported into the cells. O,p'DDA was not detected in cell homogenates or supernatants  
42 after 48h exposure to o,p'DDD, consistent with the absence of o,p'DDA production in these  
43 models. Finally, unlike o,p'DDD, we found that o,p'DDA content was undetectable in two ACC and  
44 one normal adrenal gland of mitotane-treated patients, suggesting a lack of cellular uptake and *in situ*  
45 production. Our results demonstrate that o,p'DDD, but not o,p'DDA, induces functional alterations in  
46 adrenal cells.

## 47 **Introduction**

48 Mitotane (o,p'DDD) represents the most effective drug for the treatment of advanced adrenocortical  
49 carcinoma (ACC), and is the only drug approved in the advanced setting[1, 2]. Mitotane is prescribed  
50 either in monotherapy or associated with platine-based chemotherapy and induces tumor response  
51 rates in up to one third of patients[3]. Recently, the first phase III trial performed in advanced ACC  
52 demonstrated that combination of mitotane chemotherapy with cisplatin-doxorubicin-epidoxin was  
53 more effective in prolonging progression free survival and rate of objective response than the  
54 combination of mitotane and streptozotocin[4]. In addition, mitotane is also recommended in the  
55 adjuvant setting in ACC patients at high risk of recurrence[5, 6].

56 However, the mechanism of mitotane action remains to be understood. To date, the only predictive  
57 factor of tumor response is the plasma mitotane level. Indeed, several studies have reported that a  
58 higher response rate correlates to plasma mitotane levels above 14 mg/l [7–11]. Several retrospective  
59 studies have also suggested a prolonged survival in case of plasma mitotane levels above 14 mg/l [7,  
60 9, 11] but not all [10, 12]. In addition, as neurological toxicities have been found more frequent with  
61 mitotane plasma levels above 20 mg/l [13], the recommended therapeutic window is currently between  
62 14 and 20 mg/l [2].

63 In a recent study, Hermse *et al.* analysed for the first time the respective role of plasma mitotane level  
64 and its metabolites 1,1-(o,p'-dichlorodiphenyl) acetic acid (o,p'DDA) and o,p'DDE as predictive  
65 factors of response in advanced ACC patients. This study concluded that the plasma o,p'DDD level  
66 only was associated with tumor response while no major role for its metabolites could be retrieved,  
67 questioning the real impact of o,p'DDA as an active metabolite, as previously suggested in preclinical  
68 studies.

69 At the time of ingestion, only 35% of o,p'DDD is absorbed from the gastrointestinal tract [14] and  
70 o,p'DDA has been first described as the main urinary metabolite of o,p'DDD[15, 16]. O,p'DDA is an  
71 acid derivative of o,p'DDD, obtained from two consecutive reactions of  $\beta$ -hydroxylation and  
72 dehydrochlorination[17]. The site of o,p'DDA synthesis remains unclear in humans. Martz and Straw  
73 and later Pohland *et al* were able to detect o,p'DDA in hepatic microsomes suggesting an hepatic

74 metabolism of o,p'DDD[18, 19]. Quantitative analyses measuring radiolabelled o,p'DDA in various  
75 species further revealed minute amounts of o,p'DDA in adrenal mitochondria [20–22]. From these  
76 initial observations emerged a first hypothesis that o,p'DDA could be synthesized in the liver or the  
77 adrenals and may represent the active metabolite responsible of the cytotoxic effect observed in the  
78 adrenal cortex. Others studies suggested that an adrenal metabolic transformation of o,p'DDD into  
79 o,p'DDA could be responsible of the adrenolytic effect [23]. Finally, the question on whether  
80 o,p'DDA is responsible for antitumor effects of mitotane in ACC patients remains totally unanswered.  
81 We have previously described molecular effects of o,p'DDD on cell proliferation, steroidogenesis and  
82 respiratory chain activity [24]. The aim of the present study was to investigate the exact role of  
83 o,p'DDA, in comparison with o,p'DDD. For this purpose, we first explored *in vitro* moleculareffects  
84 of o,p'DDA on cell proliferation, mitochondrial respiratory chain and steroidogenesis. We thus studied  
85 o,p'DDA conversion and uptake in human adrenocortical H295R and SW13 cell lines and human  
86 adrenal tissue samples.

## 87 **Materials and Methods**

### 88 **Human adrenocortical cells and human adrenal tissues**

89 H295R and SW13 cells were cultured in DMEM/HAM'S F-12 medium (PAA, Les Mureaux, France)  
90 supplemented with 20 mM HEPES (Life technologies, Saint Aubin, France), antibiotics (penicillin  
91 100 IU/ml, streptomycin 100 µg/mL) and 2 mM glutamine (all from PAA). The medium for H295R  
92 cell culture was enriched with 10% fetal bovine serum and a mixture of insulin/transferrin/selenium.  
93 Both cell lines (from passage 2 to 15) were cultured at 37°C in a humidified incubator with 5% CO<sub>2</sub>.  
94 Mitotane (supplied by HRA Pharma, Paris, France) and o,p'-DDA (Alsachim, Illkirch-Graffenstaden,  
95 France) were solubilized in dimethyl sulfoxide (DMSO, Sigma-Aldrich, Saint Quentin Fallavier,  
96 France) and used at 10 to 300 µM final concentrations. The percentage of DMSO in culture medium  
97 never exceeded 0.1%.

98 Tissues were obtained from six patients treated with mitotane. Five ACC patients were followed at  
99 GustaveRoussy, while patient 1, followed at Bicêtre Hospital, underwent bilateral adrenalectomy for  
100 an ectopic Cushing syndrome due a bronchopulmonary ACTH-secreting tumor. All patients signed an  
101 informed consent. Tissues were lysed in H<sub>2</sub>O using a TissueLyser apparatus (Qiagen, Courtaboeuf,  
102 France).

103

### 104 **Steroid secretion**

105 Steroid hormones concentrations were measured in the supernatants of H295R cultured cells using  
106 radioimmunoassays for 11-deoxycortisol (DiaSource Immunoassays, Louvain-la-Neuve, Belgium) and  
107 17-hydroxyprogesterone (MP Biomedicals, Ohio, USA) or chemiluminescent enzyme immunoassay for  
108 cortisol (Immulite 2000 XPI, Siemens Healthcare Diagnostics Products, Llanberis, UK). The intra-  
109 assay coefficient of variation (CV) were 5.2% and 7.7% at 3.7 and 28.3 ng/ml, and the inter-assay CV  
110 were 11.5% and 15.1% at 5.5 and 36.9 ng/ml for 11-deoxycortisol. The intra-assay CV of 17-  
111 hydroxyprogesterone radioimmunoassay were 7.8% and 8.3% at 2.7 and 13.2 ng/ml respectively and  
112 the inter-assay CV were 9.8% and 12.8% at 12.3 and 22.8 ng/ml. The intra-assay CV of cortisol assay

113 were 6.1% and 5.2% at 33 and 85 ng/ml, and the inter-assay CV were 8.2% and 6.8% at 33 and 85  
114 ng/ml.

115

### 116 **Cell proliferation analysis**

117 Cell proliferation tests were performed by using the WST1 assay (Roche, Meylan, France) according  
118 to the manufacturer's recommendations. Cells were cultured in 96-well plates and treated with 10 to  
119 300  $\mu$ M mitotane or o,p'DDA for 48 h. Optical densities were measured 4 h after addition of WST1  
120 solution (10  $\mu$ l per well) by spectrophotometry (Viktor, Perkin Elmer, Courtaboeuf, France).

121

### 122 **Respiratory chain analysis**

123 Respiratory chain activities were measured using spectrophotometric assays. H295R cells were treated  
124 with 50  $\mu$ M of mitotane (16 mg/l), 50  $\mu$ M of o,p'DDA (14 mg/l) or vehicle (DMSO) alone for 48 h  
125 and the activity of complex IV (cytochrome c oxidase, COX) was measured in a Cary 50  
126 spectrophotometer, as previously described [24]. The activity of Complex IV was normalized to that of  
127 citrate synthase activity, as an index of mitochondrial mass.

128

### 129 **Reverse Transcriptase-PCR (RT-PCR) and Quantitative real-time PCR (RT-qPCR)**

130 Total RNAs were extracted from cells with the RNeasy kit (Qiagen, Courtaboeuf, France) according to  
131 the manufacturer's recommendations. RNA was thereafter processed for RT-PCR as previously  
132 described [24]. Quantitative real-time PCR (RT-qPCR) was performed using the Fast SYBR<sup>®</sup> Green  
133 Master Mix (Life Technologies) and carried out on a StepOnePlus<sup>™</sup> Real-Time PCR System (Life  
134 Technologies) as previously described [24]. Standards and samples were amplified in duplicate and  
135 analyzed from six independent experiments. The ribosomal 18S rRNA was used as the internal control  
136 for data normalization. The relative expression of each gene was expressed as the ratio of attomoles of  
137 specific gene to femtomoles of 18S rRNA. The primer sequences of the genes analyzed by qRT-PCR  
138 are shown in the Supplemental Table 1.

139

## 140 **Western Blot analysis**

141 Total protein extracts were prepared from cells lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150  
142 mM NaCl, 5 mM EDTA, 30 mM Na pyrophosphate, 50 mM Na fluoride, 1% Triton X-100), and 1X  
143 protease inhibitor (Sigma-Aldrich, St. Louis, MO). After protein blotting on an Odyssey nitrocellulose  
144 membrane (LI-COR, Lincoln, NE, USA), blots were incubated for 1 h at RT in a blocking buffer (5%  
145 fat-free milk in Phosphate-buffer saline PBS with 0.1 % Tween 20) before an overnight incubation at  
146 4°C with a rabbit anti-Bcl2 antibody (1:500 dilution, Cell Signaling, Saint Quentin en Yvelines,  
147 France) and a mouse anti- $\alpha$ -Tubulin antibody (1:10,000 dilution, Sigma-Aldrich). After extensive  
148 washes, blots were incubated with an IRDye 800-conjugated affinity purified anti-rabbit IgG second  
149 antibody (1:15,000 dilution, Perbio Science, Brebières, France) and an IRDye 680-conjugated affinity  
150 purified anti-mouse IgG second antibody (1:15,000 dilution, Perbio Science) for 1 h at RT. After  
151 washes, proteins were visualized with an Odyssey-Fc apparatus (LI-COR). Specific signals for Bcl2  
152 were normalized by the infrared fluorescence of  $\alpha$ -Tubulin signals as determined by densitometry  
153 using the Image Studio software (LI-COR).

154

## 155 **Measurements of o,p'DDD, o,p'DDA and o,p'DDE metabolites**

156 Analyses were conducted by high performance liquid chromatography combined to an ultraviolet  
157 detection (HPLC-UV) on plasma samples of 100  $\mu$ l spiked with known amounts of *p,p'*-DDE used as  
158 an internal standards (IS) of *o,p'*-DDD and *o,p'*-DDE and *p,p'*-DDA used as an internal standards (IS)  
159 of *o,p'*-DDA measurements. *O,p'*-DDD (Mitotane), *o,p'*-DDA and *o,p'*-DDE concentrations were  
160 determined through the ratio of their peak surface area to the peak surface of known concentrations of  
161 IS. The method was validated in terms of linearity, precision and accuracy, with a threshold detection  
162 limits of 2.5 mg/l, 0.1 mg/l and 0.25 mg/l for *o,p'*-DDA, *o,p'*-DDE and *o,p'*-DDD, respectively.

163

## 164 **Statistical Analysis**

165 Results are expressed as means  $\pm$  SEM of n independent replicates performed in the same experiment  
166 or from separated experiments (n). Non-parametric Mann Whitney tests were used when appropriate  
167 and differences between groups were analyzed using non-parametric Kruskal-Wallis multiple



168 comparison test followed by a post-test of Dunn's (Prism software, GraphPad, CA). A *P* value of 0.05  
169 was considered as statistically significant (\**P*<0.05; \*\**P*<0.01; \*\*\**P*<0.001).

## 170 **Results**

### 171 **Comparative analysis of o,p'DDD and o,p'DDA impact on cell proliferation**

172 We studied the potential anti-proliferative effect of o,p'DDA on H295R and SW13 cells, testing the  
173 hypothesis that o,p'DDA might exert antitumor properties. It is well established that circulating  
174 o,p'DDA concentrations are about 5 times higher than those of o,p'DDD measured in plasma of  
175 patients treated with mitotane[11]. We thus explored functional consequences of high doses of  
176 o,p'DDA(50 to 300  $\mu$ M corresponding to 14 to 84 mg/l) compared to o,p'DDD on cell proliferation  
177 using the colorimetric solution WST1 (Fig. 1). As previously reported, we confirmed that o,p'DDD  
178 inhibited proliferation of H295R cells in a dose-dependent manner, with a significant 50% decrease  
179 when cells were exposed to 100  $\mu$ M for 48 h and a 95% inhibition when treated with 200 and 300  $\mu$ M.  
180 In sharp contrast, we showed that o,p'DDA, even at highest concentrations corresponding to its  
181 plasma circulating levels in patients, had no significant effect on H295R cell proliferation.

182

### 183 **Comparative effects of o,p'DDD and o,p'DDA on respiratory chain complex IV activity**

184 We have previously shown that mitotane significantly impaired mitochondrial respiratory chain  
185 function by selectively inhibiting enzymatic complex IV activity (cytochrome c oxidase, COX) [24].  
186 We thus evaluated the effects of o,p'DDA on COX activity in H295R cells by spectrophotometric  
187 assays. COX activity remained unaffected after 48 h exposure to 50  $\mu$ M of o,p'DDA with a mean  
188 activity of  $204 \pm 13$  nmol/min per mg protein, not significantly different from vehicle-treated cells  
189 (Fig. 2A). Likewise, activity of citrate synthase (CS), an index of the mitochondrial mass, was not  
190 modified in o,p'DDA-treated cells ( $186 \pm 8$  nmol/min per mg protein), as compared to vehicle-treated  
191 cells ( $207 \pm 6$  nmol/min per mg protein). When COX enzymatic activity were normalized to citrate  
192 synthase activity (Fig. 2B), o,p'DDA exposure did not modify mitochondrial respiratory chain activity  
193 whereas o,p'DDD significantly reduced COX/CS ratio, as anticipated. We also compared the effect of  
194 o,p'DDA and o,p'DDD on the steady-state level of mitochondrial DNA-encoded *COX2* transcript  
195 (Fig. 2C). While *COX2* expression was significantly reduced by more than 40% upon o,p'DDD  
196 treatment, o,p'DDA failed to modify *COX2* mRNA levels. Similar results were obtained with nuclear

197 DNA-encoded *COX4* transcripts (data not shown). Taken together, these results clearly demonstrate  
198 that o,p'DDA was ineffective in modulating mitochondrial activity.

199

### 200 **Consequences of o,p'DDD or o,p'DDA treatment on mitochondrial biogenesis, oxidative stress** 201 **and apoptosis.**

202 In response to mitotane-elicited respiratory chain inhibition, we have previously demonstrated a  
203 compensatory increase of mitochondrial biogenesis[24]. We therefore investigated whether or not  
204 o,p'DDA was able to induce similar compensatory mechanisms. Thus, expression of the Peroxisome  
205 proliferator-activated receptor gamma coactivator 1-related Coactivator (*PRC*), a key regulator of  
206 mitochondrial biogenesis, was quantified by RT-qPCR (Fig. 3A). We showed that o,p'DDD exposure  
207 induces a 2-fold increase in *PRC* transcript levels whereas treatment with o,p'DDA has no significant  
208 effect of *PRC* mRNA levels, consistent with the absence of effect on respiratory chain activity  
209 described above. We also evaluated consequences of o,p'DDA treatment compared to o,p'DDD on  
210 oxidative stress and apoptosis by studying the expression of *SOD2* encoding superoxide dismutase 2,  
211 an enzyme involved in reactive oxygen species (ROS)-induced detoxification and known to be induced  
212 during oxidative stress. Steady-state levels of *SOD2* messengers were significantly increased after  
213 incubation with o,p'DDD whereas they remained unchanged with o,p'DDA, suggesting that o,p'DDD  
214 but not o,p'DDA induces oxidative stress in H295R cells (Fig. 3B). We found similar results in SW13  
215 (data not shown). At a 50  $\mu$ M concentration, neither o,p'DDD nor o,p'DDA induces apoptosis as  
216 revealed by the anti-apoptotic protein B cell lymphoma 2 (*Bcl2*) expression using Western Blot.  
217 However, a drastic reduction of *Bcl2* expression was observed with 100  $\mu$ M mitotane, such reduction  
218 was not detected upon o,p'DDA incubation, suggesting that H295R cells were unaffected by high  
219 doses of o,p'DDA(Fig. 3C).

220

### 221 **Differential effects of o,p'DDD and of o,p'DDA on steroidogenesis**

222 Mitotane might exert dissociated effects with distinct time-course patterns, consisting of an early  
223 inhibitory effect on steroidogenesis followed by a later cytolytic effect responsible for adrenal cortex  
224 atrophy. To explore the impact of o,p'DDA on steroidogenesis, 17-hydroxyprogesterone,

225 deoxycortisol and cortisol concentrations were measured in the supernatants of steroid-secreting  
226 H295R cells. Exposure to 50  $\mu\text{M}$  o,p'DDA failed to inhibit secretion of 17-hydroxyprogesterone (Fig.  
227 4A) as compared to the 80% reduction observed following o,p'DDD incubation. However, when used  
228 at higher concentrations up to 300  $\mu\text{M}$ , o,p'DDA slightly but significantly reduced deoxycortisol and  
229 cortisol production without affecting 17-hydroxyprogesterone secretion of H295R cells (Fig. 4B).  
230 Expression of several genes encoding for proteins involved in steroidogenesis was studied by RT-  
231 qPCR (Fig. 4C). While 50  $\mu\text{M}$  mitotane significantly induced a 80 to 95% decrease of all genes  
232 studied, o,p'DDA failed to modify expression of *StAR* (encoding the transporter of cholesterol into  
233 mitochondria) or *CYP11A1* (encoding cholesterol desmolase) but had negligible effect on *HSD3B2*  
234 (encoding  $3\beta$ -hydroxysteroid dehydrogenase), *CYP21* (encoding 21-hydroxylase) and *CYP11B1*  
235 (encoding  $11\beta$ -hydroxylase) consistent with the anti-secretory effects of higher doses of o,p'DDA.

236

### 237 **Intracellular concentrations of o,p'DDD and o,p'DDA in human adrenocortical cells treated** 238 **with mitotane**

239 We next examined the intracellular distribution of these drugs and investigated the ability of human  
240 adrenocortical cells to uptake o,p'DDD. We also addressed the question on whether human  
241 adrenocortical H295R and SW13 cells were able to actively convert mitotane into o,p'DDA. To  
242 explore these possibilities, H295R and SW13 cells were treated with  
243 50  $\mu\text{M}$  of mitotane for 48 h and o,p'DDD and o,p'DDA concentrations were measured in cultured cell  
244 supernatants as well as in cell pellets by using HPLC-UV. As shown in Fig. 5A, when H295R cells  
245 were exposed to o,p'DDD at a theoretical concentration of 50  $\mu\text{M}$  (measured concentration of  $54.4 \pm 6.2$   
246  $\mu\text{M}$ , corresponding to a initial total amount of  $325 \pm 49 \mu\text{g}$ ), a remaining  $31.1 \pm 8.7 \mu\text{M}$  concentration  
247 ( $200 \pm 56 \mu\text{g}$ ) was recovered in cell supernatants after 48 h, suggesting an approximately 40% cellular  
248 uptake of o,p'DDD. Accordingly, we were able to measure a total amount of  $79 \pm 5.1 \mu\text{g}$  of mitotane  
249 in cell pellets (mean  $\pm$  SEM, n= 3 independent experiments) indicating that approximately 25% of  
250 o,p'DDD was actively concentrated into H295R cells while 15% of initial o,p'DDD was likely  
251 deteriorated or bound to the plate as confirmed by a cell free culture experiment. Similar results were  
252 found with SW13 cells (data not shown). Surprisingly, under these experimental conditions, despite a

253 substantial o,p'DDD uptake as measured above, o,p'DDA concentrations were below limit LOQ  
254 threshold in both cell homogenates and cell supernatants, indicating that H295R cells were unable to  
255 convert o,p'DDD into o,p'DDA and subsequently to secrete the acidic metabolite of mitotane.

256

257

#### 258 **Assessment of o,p'DDA uptake in human adrenocortical H295R and SW13 cells**

259 We next examined the ability of H295R cells to uptake o,p'DDA as compared to o,p'DDD. As shown  
260 in Fig. 5B, under experimental conditions in which H295R cells were exposed to 50  $\mu$ M of o,p'DDA  
261 during 48 h, o,p'DDA concentration measured in cell supernatant was not modified (48.75  
262  $\pm$  0.75  $\mu$ M, mean  $\pm$  SEM of three independent experiments), and was below LOQ threshold in cell  
263 homogenate, suggesting that o,p'DDA was not efficiently transported into H295R cells or was not  
264 significantly retained into cell compartment.

265

#### 266 **O,p'DDD, o,p'DDA and o,p'DDE contents in adrenal tissues of mitotane-treated patients**

267 In order to examine the tissue distribution of mitotane and its metabolites in humans, six samples of  
268 human adrenal tissue from mitotane-treated patients were collected. Patient 1 underwent bilateral  
269 adrenalectomy for an ectopic Cushing syndrome due a bronchopulmonary ACTH-secreting tumor  
270 whereas patients 2 to 6 had ACC. Cumulative doses of mitotane, duration of treatment and plasma  
271 mitotane levels are reported in Table 1. Patient 2 had a local ACC recurrence with an imaging work-up  
272 performed three months later showing a progressive disease according to RECIST criteria [25]. Thus,  
273 he received mitotane for 11 months and the last imaging work-up preceding surgery showed a stable  
274 disease according to RECIST criteria, defining this patient as responder to mitotane. Patient 3 received  
275 mitotane associated with cisplatin and etoposide, his last morphologic work-up before surgery showing  
276 a stable disease according to RECIST. Patient 4 and 5 are considered as non responders to mitotane.  
277 Indeed, patient 4, presenting with a metastatic ACC, had progressive disease according to RECIST  
278 criteria whereas patient 5 presented a local recurrence while he was treated with mitotane as an  
279 adjuvant therapy. Finally, evaluation of mitotane response for patient 6 was not possible since she died  
280 shortly after surgery without undergoing imaging work-up. We quantified o,p'DDD, o,p'DDA and

281 o,p'DDE contents in adrenal tissue homogenates measured by HPLC-UV assays (Fig. 6). Results of  
282 adrenal gland contents of mitotane and its metabolites are reported in Table 1. O,p'DDD was found  
283 20- to 40-fold higher in normal adrenal tissue compared to ACC despite lower plasma mitotane level  
284 (3.3 mg/l for Cushing's patient vs 20.03, 18.5, 23.7, 14.7 and 4 mg/l for ACC patients). More  
285 importantly, in both ACC and a normal adrenal gland of mitotane-treated patients, o,p'DDA was  
286 below limit of quantification (LOQ) threshold unlike o,p'DDD.(Fig.6).

## 287 **Discussion**

288 Mitotane remains a major therapeutic option in ACC patients and no new pharmacological strategy  
289 has been proposed for the past 30 years [1, 2]. However, only one third of patients are considered as  
290 responders and the only predictive factor of response is plasma mitotane level, which has to be  
291 between 14 and 20 mg/l, a therapeutic window reached after a mean of three months of treatment [8,  
292 26, 27]. For this reason, elucidation of mitotane mechanism of action constitutes a major field of  
293 research. Preclinical studies have suggested that o,p'DDA could be the active metabolite of o,p'DDD.  
294 The role of o,p'DDA compound has also been recently reevaluated in ACC patients. In a first study,  
295 mean o,p'DDA plasma concentrations measured in mitotane-treated patients were found five times  
296 higher than those of o,p'DDD. However, the median time to reach maximal o,p'DDA values was  
297 found shorter than for o,p'DDD (11 vs 55 days, respectively), suggesting that o,p'DDA might  
298 constitute an earlier predictor of response [27]. In a second study, o,p'DDA plasma level above 92  
299 mg/l could be more specific than o,p'DDD above 14 mg/l in the prediction of tumor response but its  
300 mean level was not correlated with tumor response [11]. Based on the lack of convincing clinical  
301 evidence for a major role of o,p'DDA as an active antitumor metabolite of mitotane in ACC patients,  
302 we aimed at reevaluating the exact pharmacological contribution of o,p'DDA by studying its  
303 molecular effects *in vitro* on human adrenocortical H295R and SW13 cells and by investigating its  
304 adrenal gland distribution in mitotane-treated patients.

305 In order to rule out an antitumor role of o,p'DDA, we compared o,p'DDA and o,p'DDD action on cell  
306 proliferation, respiratory chain, mitochondrial biogenesis, oxidative stress, apoptosis and  
307 steroidogenesis. To the best of our knowledge, direct functional consequences of o,p'DDA have never  
308 been studied before. We first demonstrate that o,p'DDA did not exert any anti-proliferative effect on  
309 adrenocortical cells, even at high concentrations up to 300  $\mu$ M (84 mg/l) corresponding to mean  
310 plasma o,p'DDA levels measured in mitotane-treated patients. Second, functional assays showed that  
311 low concentrations such as 50  $\mu$ M o,p'DDA had no significant impact on mitochondrial respiratory  
312 chain activity and biogenesis, and were not able to induce H295R cell oxidative stress or apoptosis in  
313 sharp contrast to o,p'DDD, as previously described [28, 29].

314 We quantified for the first time o,p'DDD and its metabolites in 6 human samples of adrenal tissues.  
315 Patients rarely receive mitotane before undergoing surgery that may explain the low number of  
316 available samples. We were unable to quantify o,p'DDA metabolite as its concentration was below  
317 LOQ, strongly suggesting a lack of *in situ* production and an absence of uptake of circulating  
318 metabolite by adrenal glands. Along this line, o,p'DDA was undetectable in human adrenocortical  
319 H295R or SW13 cell supernatants and pellets after a 48 h exposure with 50  $\mu$ M mitotane providing  
320 additional arguments against an active metabolism of o,p'DDD in human adrenocortical cortex.  
321 Further studies should be performed in primary cultures of ACC to confirm the findings of the current  
322 study. Previous studies identified o,p'DDA in adrenals of bovines, dogs or rats treated with  
323 radiolabelled mitotane [19–21] but not all [22]. Of note, in these studies, intra-adrenal radiolabelled-  
324 o,p'DDA represented less than 5% of total radioactivity. In contrast, an hepatic production of  
325 o,p'DDA has been previously reported, as demonstrated by metabolic conversion of o,p'DDD with  
326 hepatic microsomes of dogs, rats or bovines [18, 19]. Similarly, an active hepatic metabolism of  
327 o,p'DDD is likely given the mitotane-induced *CYP3A4* expression in the liver [30, 31]. Moreover,  
328 elevated plasma mitotane levels were found to be associated with a gene polymorphism of *CYP2B6*  
329 encoding a cytochrome known to catalyze the metabolism of o,p'DDT, structurally close to  
330 o,p'DDD [32]. Although our study does not rule out a production of o,p'DDA outside the adrenal  
331 gland, likely in liver as previously suggested, our results strongly suggest a lack of capture by adrenal  
332 cells and therefore a low if any antitumor activity of o,p'DDA.

333 We confirmed an uptake of o,p'DDD by H295R cells [29] and demonstrated that up to 25% of  
334 o,p'DDD was measured in cell pellets, suggesting that o,p'DDD itself could be the active compound.  
335 Interestingly, we discovered that o,p'DDD content measured into normal human adrenal gland  
336 collected after surgery of a mitotane-treated ectopic Cushing patient was much higher than that  
337 quantified in five resected ACC, while plasma circulating mitotane levels were much lower in the  
338 former patient compared to the latter (see Table 1). These observations strongly support the notion that  
339 the rate of mitotane uptake in the adrenal gland might be related to the specific transport processes  
340 active in normal adrenocortical cells while weakly expressed or absent in ACC. In ACC, o,p'DDD  
341 content was higher in adrenal tissue of the patient presenting with stable disease compared to the



342 adrenal tissues of other patients. However, no conclusion could be drawn from this observation given  
343 the small number of samples. Altogether, our experiments bring decisive arguments to exclude that  
344 o,p'DDA is the active metabolite responsible for adrenolytic effects of mitotane.

345 In patients, mitotane is known to exert dual effects on adrenal cells including an early inhibition of  
346 steroidogenesis and a late destruction of adrenal tissue [33]. Here, o,p'DDA may potentially exert an  
347 inhibitory effect of steroidogenesis. Indeed, although o,p'DDA up to 300  $\mu$ M did not inhibit 17-  
348 hydroxyprogesterone secretion, we showed a slight and significant reduction in the expression of some  
349 (*HSD3B2*, *CYP21* and *CYP11B1*) but not all genes encoding steroidogenic enzymes, consistent with  
350 the weak inhibition of cortisol secretion at 300  $\mu$ M o,p'DDA. Accordingly, it has been reported that  
351 the aromatic moiety of the o,p'DDD molecule could be responsible for an anti-steroidogenic effect  
352 whereas the aliphatic group of this compound could account for its cytolytic effect as previously  
353 suggested [34]. Indeed, o,p'DDD and m,p'DDD which display similar aromatic structures inhibited  
354 steroidogenesis while p,p'DDD that exhibits a different aromatic cycle, was unable to inhibit  
355 steroidogenesis [35]. Thus, these findings pointed to the importance of the aliphatic group, notably the  
356 dihalogenated methane carbon which is critical for the cytotoxic activity [34], yet lacking in the  
357 o,p'DDA structure.

358 To conclude, our results indicate for the first time the absence of adrenal cell metabolism and uptake of  
359 o,p'DDA and provide *in vitro* evidence that o,p'DDA is very unlikely an effective metabolite of  
360 mitotane to control adrenocortical cell proliferation and to impact mitochondrial respiratory chain  
361 activity. By contrast, we confirm major interaction of o,p'DDD with adrenal cell functions and  
362 proliferation and unambiguously demonstrate a high cellular uptake of o,p'DDD by adrenal cells.  
363 Taken together, our results indicate that research on mitotane mechanism of action should focus on  
364 o,p'DDD.

365 **Fundings**

366 This work was supported by the Institut National de la Santé et de la Recherche Médicale (Inserm) and  
367 Université Paris-Sud. SH is recipient of a fellowship from HRA Pharma Laboratories (Bourse  
368 CIFRE).

369 **Author contributions**

370 SH, AP, EB and ML designed the study; SH, AS, AHS and SBT performed the experiments; SH, AS,  
371 AHS, SBT, EB and ML analyzed the results; AP, SV, ST and JY helped interpret the data and  
372 participated in discussions; SH, SV, EB and ML wrote the paper; all the authors have read, revised and  
373 approved the manuscript.

374 **Acknowledgements**

375 The authors are indebted to HRA Pharma for supporting this research.

376 **Declaration of interest**

377 SH is recipient of a fellowship from HRA Pharma Laboratories (Bourse CIFRE).

378 The authors declare that they have no conflict of interest.

379

380

381 **References**

- 382 1. Schteingart DE, Doherty GM, Gauger PG, et al. (2005) Management of patients with adrenal  
383 cancer: recommendations of an international consensus conference. *Endocr Relat Cancer*  
384 12:667–680. doi: 10.1677/erc.1.01029
- 385 2. Berruti A, Baudin E, Gelderblom H, et al. (2012) Adrenal cancer: ESMO Clinical Practice  
386 Guidelines for diagnosis, treatment and follow-up. *Ann Oncol Off J Eur Soc Med Oncol*  
387 ESMO 23 Suppl 7:vii131–138. doi: 10.1093/annonc/mds231
- 388 3. Baudin E, Leboulleux S, Al Ghuzlan A, et al. (2011) Therapeutic management of advanced  
389 adrenocortical carcinoma: what do we know in 2011? *Horm Cancer* 2:363–371. doi:  
390 10.1007/s12672-011-0094-2
- 391 4. Fassnacht M, Terzolo M, Allolio B, et al. (2012) Combination chemotherapy in advanced  
392 adrenocortical carcinoma. *N Engl J Med* 366:2189–2197. doi: 10.1056/NEJMoa1200966
- 393 5. Berruti A, Fassnacht M, Baudin E, et al. (2010) Adjuvant therapy in patients with adrenocortical  
394 carcinoma: a position of an international panel. *J Clin Oncol Off J Am Soc Clin Oncol*  
395 28:e401–402; author reply e403. doi: 10.1200/JCO.2009.27.5958
- 396 6. Else T, Williams AR, Sabolch A, et al. (2014) Adjuvant therapies and patient and tumor  
397 characteristics associated with survival of adult patients with adrenocortical carcinoma. *J Clin*  
398 *Endocrinol Metab* 99:455–461. doi: 10.1210/jc.2013-2856
- 399 7. Haak HR, Hermans J, van de Velde CJ, et al. (1994) Optimal treatment of adrenocortical carcinoma  
400 with mitotane: results in a consecutive series of 96 patients. *Br J Cancer* 69:947–951.
- 401 8. Baudin E, Pellegriti G, Bonnay M, et al. (2001) Impact of monitoring plasma 1,1-  
402 dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with  
403 adrenocortical carcinoma. *Cancer* 92:1385–1392.
- 404 9. Malandrino P, Al Ghuzlan A, Castaing M, et al. (2010) Prognostic markers of survival after  
405 combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma  
406 (ACC). *Endocr Relat Cancer*. doi: 10.1677/ERC-09-0341
- 407 10. Wängberg B, Khorram-Manesh A, Jansson S, et al. (2010) The long-term survival in  
408 adrenocortical carcinoma with active surgical management and use of monitored mitotane.  
409 *Endocr Relat Cancer* 17:265–272. doi: 10.1677/ERC-09-0190
- 410 11. Hermsen IG, Fassnacht M, Terzolo M, et al. (2011) Plasma concentrations of o,p’DDD, o,p’DDA,  
411 and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results  
412 of a retrospective ENS@T multicenter study. *J Clin Endocrinol Metab* 96:1844–1851. doi:  
413 10.1210/jc.2010-2676
- 414 12. Ayala-Ramirez M, Jasim S, Feng L, et al. (2013) Adrenocortical carcinoma: clinical outcomes and  
415 prognosis of 330 patients at a tertiary care center. *Eur J Endocrinol Eur Fed Endocr Soc*  
416 169:891–899. doi: 10.1530/EJE-13-0519
- 417 13. Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D (1984) The treatment of adrenocortical  
418 carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. *Eur J Cancer*  
419 *Clin Oncol* 20:47–53.
- 420 14. MOY RH (1961) Studies of the pharmacology of o,p’DDD in man. *J Lab Clin Med* 58:296–304.

- 421 15. Sinsheimer JE, Guilford J, Bobrin LJ, Schteingart DE (1972) Identification of o,p'-  
422 dichlorodiphenyl acetic acid as a urinary metabolite of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-  
423 2,2-dichloroethane. *J Pharm Sci* 61:314–316.
- 424 16. Reif VD, Sinsheimer JE (1975) Metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-  
425 dichloroethane (o,p'-DDD) in rats. *Drug Metab Dispos Biol Fate Chem* 3:15–25.
- 426 17. Schteingart DE (2007) Adjuvant mitotane therapy of adrenal cancer - use and controversy. *N Engl*  
427 *J Med* 356:2415–2418. doi: 10.1056/NEJMe078087
- 428 18. Martz F, Straw JA (1980) Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-  
429 chlorophenyl)-2,2-dichloroethane (o,p',-DDD). Correlation between adrenocorticolytic  
430 activity and metabolic activation by adrenocortical mitochondria. *Drug Metab Dispos Biol*  
431 *Fate Chem* 8:127–130.
- 432 19. Pohland RC, Counsell RE (1985) In vitro and in vivo metabolism of a radioiodinated analog of 1-  
433 (2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane. *Drug Metab Dispos Biol Fate Chem*  
434 13:113–115.
- 435 20. Martz F, Straw JA (1977) The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-  
436 dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to  
437 mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. *Drug*  
438 *Metab Dispos Biol Fate Chem* 5:482–486.
- 439 21. Cai W, Benitez R, Counsell RE, et al. (1995) Bovine adrenal cortex transformations of mitotane  
440 [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-  
441 isomers. *Biochem Pharmacol* 49:1483–1489.
- 442 22. Cai W, Counsell RE, Djanegara T, et al. (1995) Metabolic activation and binding of mitotane in  
443 adrenal cortex homogenates. *J Pharm Sci* 84:134–138.
- 444 23. Cai W, Counsell RE, Schteingart DE, et al. (1997) Adrenal proteins bound by a reactive  
445 intermediate of mitotane. *Cancer Chemother Pharmacol* 39:537–540.
- 446 24. Hescot S, Slama A, Lombès A, et al. (2013) Mitotane alters mitochondrial respiratory chain  
447 activity by inducing cytochrome c oxidase defect in human adrenocortical cells. *Endocr Relat*  
448 *Cancer* 20:371–381. doi: 10.1530/ERC-12-0368
- 449 25. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid  
450 tumours: revised RECIST guideline (version 1.1). *Eur J Cancer Oxf Engl* 1990 45:228–247.  
451 doi: 10.1016/j.ejca.2008.10.026
- 452 26. Maucière-Denost S, Leboulleux S, Borget I, et al. (2012) High-dose mitotane strategy in  
453 adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the  
454 first 3 months of follow-up. *Eur J Endocrinol Eur Fed Endocr Soc* 166:261–268. doi:  
455 10.1530/EJE-11-0557
- 456 27. Kerkhofs TM, Baudin E, Terzolo M, et al. (2013) Comparison of two mitotane starting dose  
457 regimens in patients with advanced adrenocortical carcinoma. *J Clin Endocrinol Metab*  
458 98:4759–4767. doi: 10.1210/jc.2013-2281
- 459 28. Lehmann TP, Wrzesiński T, Jagodziński PP (2013) The effect of mitotane on viability,  
460 steroidogenesis and gene expression in NCI-H295R adrenocortical cells. *Mol Med Rep*  
461 7:893–900. doi: 10.3892/mmr.2012.1244

- 462 29. Poli G, Guasti D, Rapizzi E, et al. (2013) Morpho-functional effects of mitotane on mitochondria  
463 in human adrenocortical cancer cells. *Endocr Relat Cancer*. doi: 10.1530/ERC-13-0150
- 464 30. Chortis V, Taylor AE, Schneider P, et al. (2013) Mitotane therapy in adrenocortical cancer induces  
465 CYP3A4 and inhibits 5 $\alpha$ -reductase, explaining the need for personalized glucocorticoid and  
466 androgen replacement. *J Clin Endocrinol Metab* 98:161–171. doi: 10.1210/jc.2012-2851
- 467 31. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Takeuchi Y (2013) Mitotane induces CYP3A4  
468 expression via activation of the steroid and xenobiotic receptor. *J Endocrinol* 216:297–305.  
469 doi: 10.1530/JOE-12-0297
- 470 32. D'Avolio A, De Francia S, Basile V, et al. (2013) Influence of the CYP2B6 polymorphism on the  
471 pharmacokinetics of mitotane. *Pharmacogenet Genomics* 23:293–300. doi:  
472 10.1097/FPC.0b013e3283606cb2
- 473 33. BERGENSTAL DM, DAO TLY (1953) Management of Addison's disease in adrenalectomized  
474 patients. *Bull N Y Acad Med* 29:295–306.
- 475 34. Schteingart DE, Sinsheimer JE, Benitez RS, et al. (2012) Structural requirements for mitotane  
476 activity: development of analogs for treatment of adrenal cancer. *Anticancer Res* 32:2711–  
477 2720.
- 478 35. Asp V, Cantillana T, Bergman A, Brandt I (2010) Chiral effects in adrenocorticolytic action of  
479 o,p'-DDD (mitotane) in human adrenal cells. *Xenobiotica Fate Foreign Compd Biol Syst*  
480 40:177–183. doi: 10.3109/00498250903470230

481

482

483 **Figures legends**

484 **Figure 1**

485 Dose-dependent impact of increasing concentrations of o,p'DDD and o,p'DDA (10-300  $\mu$ M) on the  
486 proliferation index of human adrenocortical H295R cells after 48 h as determined by WST1 assays.  
487 Results are expressed as mean percentage  $\pm$  SEM of 6 to 18 independent determinations, values of  
488 vehicle-treated cells being arbitrarily set at 100%. O,p'DDD inhibits cell proliferation in a dose-  
489 dependent manner whereas o,p'DDA has no significant impact on cell proliferation. \* $P$ <0.05 and  
490 \*\*\* $P$ <0.001, Mann-Whitney  $U$  test.

491

492 **Figure 2**

493 Enzymatic activities of complex IV (cytochrome c oxidase, COX) (A) and ratio between complex IV  
494 and citrate synthase activities (B) measured in cell homogenates of cells treated for 48 h with 50  $\mu$ M  
495 of o,p'DDD or o,p'DDA. The enzymatic activities were measured using spectrophotometry as  
496 described in the Materials and Methods section. Results are expressed as nmol/min per mg proteins  
497 (A) or as percentage of control ratio arbitrarily set at 100%. Each experiment was repeated three times.  
498 Expression of *COX2* (C). H295R cells were treated with 50  $\mu$ M o,p'DDD or o,p'DDA for 48 h.  
499 Relative mRNA expression of each gene was determined using RT-qPCR. Results are means  $\pm$  SEM  
500 of six different experiments performed in duplicate and are expressed as percentage of the relative  
501 expression in vehicle-treated cells, arbitrarily set at 100%. O,p'DDA has no effect on respiratory chain  
502 activity or gene expression. \* $P$ <0.05 and \*\*\* $P$ <0.001, Mann-Whitney  $U$  test.

503

504 **Figure 3**

505 Expression of *PRC* (A) and *SOD2* (B). H295R cells were treated with 50  $\mu$ M o,p'DDD or o,p'DDA  
506 for 48 h. Relative mRNA expression of each gene was determined using RT-qPCR. Results are means  
507  $\pm$  SEM of six different experiments performed in duplicate and are expressed as percentage of the  
508 relative expression in vehicle-treated cells, arbitrarily set at 100%.

509 Steady-state levels of Bcl2 protein (anti-apoptotic factor) by Western Blot with anti-Bcl2 and anti-  
510 tubulin antibodies. H295R cells were treated with 50 or 100  $\mu$ M o,p'DDD or o,p'DDA for 48 h.

511 O,p'DDD is able to increase mitochondrial biogenesis, to induce oxidative stress and apoptosis  
512 whereas o,p'DDA fails to exert similar effects. \* $P$ <0.05 and \*\*\* $P$ <0.001, Mann-Whitney  $U$  test.

513

#### 514 **Figure 4**

515 Inhibition of 17-hydroxyprogesterone (17-OHP) in the steroid-secreting H295R cells with o,p'DDD  
516 but not with o,p'DDA (A). Cells were cultured with 50  $\mu$ M mitotane (o,p'DDD) for 48 h and the 17-  
517 OHP concentrations were measured in the cell supernatants by radioimmunometric assays. Results are  
518 mean percentage  $\pm$  SEM. of 3 independent determinations and are expressed as percentage of secretion  
519 under basal conditions in vehicle-treated cells; arbitrarily set at 100% (mean 17-OHP secretion was  
520 799 ng /48 h /mg protein).

521 Inhibition of 17-hydroxyprogesterone (17-OHP), deoxycortisol and cortisol in the steroid-secreting  
522 H295R cells with high doses of o,p'DDA (B). Cells were cultured with 100 or 300  $\mu$ M o,p'DDA for  
523 48 h and the steroid concentrations were measured in the cell supernatants by radioimmunometric  
524 assays. Results are mean percentage  $\pm$  SEM. of 3 independent determinations and are expressed as  
525 percentage of secretion under basal conditions in vehicle-treated cells, arbitrarily set at 100% (mean  
526 deoxicortisol and cortisol secretion were 848 ng/48h/mg protein and 207ng/48h/mg protein  
527 respectively).

528 Expression of genes encoding proteins involved in steroidogenesis (C). H295R cells were treated with  
529 50  $\mu$ M o,p'DDD or o,p'DDA for 48 h. Relative mRNA expression of each gene was determined using  
530 RT-qPCR. Results are means  $\pm$  SEM of 6 different experiments performed in duplicate and are  
531 expressed as percentage of the relative expression in vehicle-treated cells, arbitrarily set at 100%.  
532 O,p'DDD inhibits steroid production and gene expressions whereas o,p'DDA has a weaker or no  
533 effect. \* $P$ <0.05 and \*\*\* $P$ <0.001, Mann-Whitney  $U$  test.

534

535

536

537 **Figure 5**

538 o,p'DDD concentrations as measured by HPLC-UV in the supernatants of cultured H295R cells before  
539 and after 48 h exposure to mitotane as well as in cell pellet after 48 h mitotane treatment (A).  
540 Concentrations of o,p'DDD and o,p'DDA as assessed by UV-HPLC in cultured H295R cell  
541 supernatant after a 48 h exposure to o,p'DDD or o,p'DDA (B). Results are expressed as mean  
542 percentage  $\pm$  SEM of the initial o,p'DDD concentration in cell culture medium at time zero (T0). Each  
543 experiment was repeated 3 to 5 times. H295R cell uptake represents 40% of initial o,p'DDD yet  
544 o,p'DDA was not recovered in the cell pellet whether H295R cells were incubated with o,p'DDD or  
545 o,p'DDA. \* $P$ <0.05 and \*\* $P$ <0.01, Mann-Whitney  $U$  test.

546

547 **Figure 6**

548 HPLC-UV analysis of o,p'DDD and o,p'DDE in human adrenal tissues: a normal adrenal (A) and an  
549 ACC (B), with p,p'DDD as the internal standard. O,p'DDD is higher in normal adrenal compared to  
550 ACC. O,p'DDE is undetectable in human adrenal tissues of patients treated with mitotane.  
551 HPLC-UV analysis of o,p'DDA in human ACC (C) compared to a point of the range at 25 mg/l (D),  
552 with p,p'DDA as the internal standard. O,p'DDA is undetectable in human adrenal tissue of patient  
553 treated with mitotane.

554

555



556 **Table 1**

557 **O,p'DDD, o,p'DDA and o,p'DDE concentrations in human adrenal tissues samples of mitotane-**  
 558 **treated patients**

559

Patients (#)	Clinicalpresentation	Treatment duration (months)	Cumulative dose (g)	Plasma mitotane level (mg/l)	O,p'DDD (µg per 10mg of tissue)	O,p'DDE (µg per 10 mg of tissue)	O,p'DDA (µg per 10 mg of tissue)
1	Ectopic Cushing	5	225	3.3*	17.2	< LOQ	< LOQ
2	ACC	11	720	20.03**	0.79	0.16	< LOQ
3	ACC	21	1470	18.5**	0.21	< LOQ	< LOQ
4	ACC	8	765	23.7**	0.44	0.11	< LOQ
5	ACC	10	870	14.7**	0.65	< LOQ	< LOQ
6	ACC	2	180	4*	4.1	0.6	< LOQ

560

561 An informed consent was obtained for each patient. O,p'DDD and its metabolites were measured in  
 562 tissue homogenates using HPLC-UV analysis.

563 LOQ: limit of quantification.

564 \* Plasma mitotane level measured two weeks before surgery

565 \*\* Mean of 4 to 15 plasma mitotane levels assessed during mitotane treatment and before surgery

566

567

568  
569  
570

## Supplemental Table 1

Primer sequences of the genes analyzed by RT-qPCR (5' – 3')

---

Gene	Amplicon	Sensesequene	Antisensesequene
18S	71 pb	GTGCATGGCCGTTCTTAGTTG	CATGCCAGAGTCTCGTTCGTT
StAR	121 pb	GCCACAGACTTCGGGAACAT	AGTAGCCACGTAAGTTTGGTCTTAGAG
Cyp11A1	149pb	CGATTACCGTGGCATCCTCTA	AGGTTGCGTGCCATCTCATAAC
HSD3B2	149 pb	GGAGGAAGCCAAGCAGAAAA	CAGGTGGGTGGAGTTTGATGA
Cyp21	180pb	GGCTGAAGCAGGCCATAGAG	CCACCCCTTGGAGCATGTAG
Cyp11B1	99 pb	GGAGACACTAACCCAAGAGGACAT	ACGTGATTAGTTGATGGCTCTGAA
COX 2	194 pb	TACGGCGGACTAATCTTCAA	CCGGGAATTGCATCTGTTTT
PRC	201 pb	CCACGTACTCAGGGTT	GGTCTAGGGGCCTCTT
SOD2	60 pb	GCAAGGAACAACAGGCCTTA	GTAGTAAGCGTGCTCCCACAC

---

571  
572